Lindbrook Capital, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 363 shares of CRNX stock, worth $13,558. This represents 0.0% of its overall portfolio holdings.
Number of Shares
363
Previous 354
2.54%
Holding current value
$13,558
Previous $15,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$235 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$233 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$220 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$185 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$167 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.01B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...